Literature DB >> 35867699

Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant.

Sammy Huygens1, Bas Oude Munnink2, Arvind Gharbharan1, Marion Koopmans2, Bart Rijnders1.   

Abstract

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6, viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Entities:  

Keywords:  Omicron; SARS-CoV-2; immunocompromised; resistance; sotrovimab

Year:  2022        PMID： 35867699      PMCID： PMC9384506          DOI： 10.1093/cid/ciac601

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


  6 in total

1.  Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases.

Authors:  Daniele Focosi; Federica Novazzi; Andreina Baj; Francesca Drago Ferrante; Sara Boutahar; Angelo Paolo Genoni; Daniela Dalla Gasperina; Fabrizio Maggi
Journal:  J Clin Virol Plus       Date:  2022-06-28

2.  Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial.

Authors:  Arvind Gharbharan; Carlijn Jordans; Lisa Zwaginga; Grigorios Papageorgiou; Nan van Geloven; Peter van Wijngaarden; Jan den Hollander; Faiz Karim; Elena van Leeuwen-Segarceanu; Robert Soetekouw; Jolanda Lammers; Douwe Postma; Linda Kampschreur; Geert Groeneveld; Francis Swaneveld; C Ellen van der Schoot; Hannelore Götz; Bart Haagmans; Marion Koopmans; Susanne Bogers; Corine Geurtsvankessel; Jaap Jan Zwaginga; Casper Rokx; Bart Rijnders
Journal:  Clin Microbiol Infect       Date:  2022-08-23       Impact factor: 13.310

3.  Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy.

Authors:  Daniele Focosi; Marco Tuccori
Journal:  Pathogens       Date:  2022-07-22

4.  Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia.

Authors:  Giovanni Belcari; Alberto Conti; Alessandro Mazzoni; Maria Lanza; Paola Mazzetti; Daniele Focosi
Journal:  Life (Basel)       Date:  2022-07-21

5.  Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab.

Authors:  Clara Luzia Magnus; Andreas Hiergeist; Philipp Schuster; Anette Rohrhofer; Jan Medenbach; André Gessner; David Peterhoff; Barbara Schmidt
Journal:  Front Immunol       Date:  2022-08-24       Impact factor: 8.786

Review 6.  The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies.

Authors:  Daniele Focosi; Scott McConnell; Arturo Casadevall
Journal:  Drug Resist Updat       Date:  2022-10-03       Impact factor: 22.841
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.